Paliperidone Viatris

Paliperidone, the active ingredient in Paliperidone Viatris, is an atypical antipsychotic presented as a solid oral dosage form for oral use. It treats schizophrenia and schizoaffective disorder in adults. GNH USA supplies Paliperidone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Paliperidone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Paliperidone is an atypical antipsychotic that modulates dopamine and serotonin pathways in psychotic disorders.

- Schizophrenia: Reduces the frequency and severity of psychotic episodes and improves overall functioning. - Schizoaffective disorder: Alleviates both mood and psychotic symptoms, supporting long‑term stability. - Maintenance therapy: Helps prevent relapse in patients with a history of recurrent psychotic episodes.

Paliperidone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Akathisia: Restlessness and an urge to move constantly. - Weight gain: Increased appetite leading to modest weight increase. - Somnolence: Drowsiness or feeling unusually sleepy. - Dry mouth: Reduced salivation causing a dry sensation in the mouth. - Constipation: Decreased bowel motility resulting in infrequent stools. - Elevated prolactin: Hormonal changes that may cause menstrual irregularities or galactorrhea.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: Potentially life‑threatening reaction with fever, muscle rigidity and autonomic instability. - Tardive dyskinesia: Persistent involuntary movements, often of the face and tongue. - Seizures: Increased risk of convulsive episodes, particularly at higher doses. - Orthostatic hypotension: Marked drop in blood pressure upon standing, causing dizziness or fainting. - Cardiac arrhythmias: QT‑interval prolongation that may predispose to serious rhythm disturbances.

When prescribing Paliperidone, clinicians should consider several safety aspects.

- Cardiovascular assessment: Evaluate baseline ECG and monitor for QT prolongation. - Metabolic monitoring: Track weight, glucose and lipid profiles regularly. - Prolactin levels: Check for hyperprolactinemia if menstrual changes or galactorrhea occur. - Elderly patients: Use lower initial doses and monitor for falls and sedation. - Pregnancy and lactation: Weigh potential benefits against risks; avoid unless clearly needed. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture and direct sunlight.

Paliperidone can interact with several medication classes, requiring careful management.

Major Interactions (Avoid):\n- Strong CYP3A4 inhibitors: May increase paliperidone plasma concentrations and heighten adverse‑event risk. - QT‑prolonging drugs: Combined effect can raise the likelihood of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CNS depressants: May enhance sedation and impair psychomotor performance. - Antihypertensive agents: Potential additive effect on blood pressure lowering. - Drugs affecting renal excretion: Altered clearance may require dose adjustment.